ARA-290 (Cibinetide) – Kodiac biolabs

Plain-language summaryIntrigue 78 / 100

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix B portion of erythropoietin. It activates a tissue-protective receptor without raising hematocrit. Investigated for neuropathic pain. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

62/100

Cleanly dissects EPO’s tissue-protective arm from erythropoiesis; novel IRR mechanism with real Phase 2 neuropathy data

Here’s the thing about ARA-290: its core insight is genuinely elegant. Erythropoietin does two very different jobs through two very different receptor complexes, and Araim’s group figured out you can have one without the other. The erythropoietic activity runs through the classical EPO homodimer. The tissue-protective, anti-inflammatory side runs through the heteromeric innate repair receptor (IRR), assembled around the CD131 beta chain it shares with IL-3 and IL-5 receptors. Brines, Cerami, and colleagues rationally designed ARA-290’s 11-residue helix B sequence to engage the IRR selectively while leaving the homodimer untouched. That isn’t lucky fragment screening; that’s real structure-guided design, and it shows.

What we like about the evidence here is the indication specificity. Small fiber neuropathy in sarcoidosis is a genuinely underserved corner of neurology. The autonomic and sensory small fibers that SFN destroys are exactly what IRR signaling appears to defend. The Phase 2 RCT in sarcoid-associated SFN showed statistically significant reductions in neuropathic pain scores alongside improvements in autonomic measures. Thats a human signal in real patients with a real unmet need, not a hopeful extrapolation from rodent nerve ligation. The bench-to-clinic translation has, at minimum, partially happened.

The limits are worth being clear about. Araim is essentially the sole development vehicle for this compound, and the trial base is still Phase 2. The mechanism literature from Brines and Cerami is solid and these are credible people with serious EPO biology credentials going back two decades, but independent multi-lab replication of the IRR pharmacology in ARA-290-specific contexts is thin. That’s not a fatal problem; it’s a real constraint on how confident you can be in the evidence package relative to compounds with broader investigator adoption.

For bench investigators, the probe value here is non-trivial. Historically, any EPO-related biology experiment had to account for the erythropoietic confound: change EPO signaling and youre also changing red cell mass, oxygen delivery, and a cascade of secondary effects. ARA-290 removes that variable cleanly. If you’re studying neuroprotection, neuroinflammation, or IRR-mediated tissue repair, this is one of the only tools that lets you probe that biology without the hematological noise. That specificity has real utility across a broader range of research contexts than the SFN indication alone implies.

We think this is a compound worth tracking for anyone working in EPO signaling, innate repair biology, or neuroprotective peptides generally. Its not top-priority for most programs, but the mechanism is genuinely novel, the clinical backing is better than most peptides in this space ever achieve, and the IRR axis may turn out to be relevant to a much wider range of tissue-injury and neuroinflammatory contexts. The score reflects real promise constrained by early-stage single-sponsor evidence, not a knock on the biology.

Novelty: 62
Mechanism promise: 70
In-category differentiation: 68
Evidence quality: 50
Translational signal: 52
Research bench value: 62

Rationale ARA-290 earns its score primarily on the elegance of its receptor selectivity design and genuine Phase 2 RCT backing in sarcoidosis-associated SFN; evidence quality is constrained by single-sponsor development and no Phase 3 replication yet, which keeps the overall in the low 60s rather than pushing toward the established-active tier.

EPO-derived helix B peptide

An 11-amino-acid fragment of erythropoietin’s helix B with tissue-protective activity but without erythropoietic activity.

Abstract

ARA-290 (Cibinetide; Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; CAS 1208243-50-8) is an 11-residue peptide derived from the alpha-helix B region of erythropoietin (EPO). The peptide retains the tissue-protective and anti-inflammatory activity of EPO (mediated through the heteromeric EPO/CD131 innate repair receptor) without the erythropoietic activity (mediated through the EPO receptor homodimer). The compound was developed by Araim Pharmaceuticals for diabetic neuropathy, sarcoidosis-associated small fiber neuropathy, and other neuropathic pain indications. Phase 2 trials in sarcoidosis-associated SFN showed reductions in neuropathic pain and improvements in autonomic measures. Doses are 4 mg subcutaneously per day in clinical trials.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-126Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.